|Bid||214.23 x 800|
|Ask||216.56 x 1100|
|Day's range||211.52 - 217.10|
|52-week range||49.91 - 252.78|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||194.87|
Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.
Shares of BioNTech (NASDAQ: BNTX) were down 10.2% for the week, as of the market close on Thursday. Moderna (NASDAQ: MRNA) stock fell 7.5%, and Novavax (NASDAQ: NVAX) tumbled 14.2%. The decline for Novavax might be the most puzzling.
First program from BioNTech’s fully-owned mRNA cancer vaccine platform FixVac treats patients in a randomized clinical Phase 2 clinical trial Phase 2 trial is based on positive results from Phase 1 Lipo-MERIT trial that demonstrated a favorable safety profile for BNT111 as well as durable objective responses observed in patients with melanoma who had progressed following prior checkpoint blockadeTrial is enrolling a total of 120 patients at clinical trial sites in the European Union, the United